Guardant Health (GH)
(Delayed Data from NSDQ)
$30.50 USD
+0.44 (1.46%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $30.60 +0.10 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GH 30.50 +0.44(1.46%)
Will GH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GH
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
Stock Market News for May 13, 2024
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Other News for GH
Exact Sciences: Still No Reason To Own
Guardant: Double-Digit Sales Projections Come At A Cost
Guardant Health Poised for Growth: FDA Approval, Strategic Financial Management, and Market Penetration Fuel Buy Rating
Guardant Health Inc's Meteoric Rise: Unpacking the 51% Surge in Just 3 Months
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer